期刊文献+

重症胰腺炎患者应用血液净化治疗对于控制全身炎性反应综合征的效果研究 被引量:3

Application of blood purification therapy in patients with severe acute pancreatitis to treat systemic inflammatory response syndrome
原文传递
导出
摘要 目的:分析重症胰腺炎患者应用血液净化治疗对于控制全身炎性反应综合征的效果。方法:随机选取2013年4月—2014年4月于本院就诊的90例重症胰腺炎患者作为研究对象,并依据数字表法将其随机分为A组及B组,每组45例;A组患者进行间歇性血液净化,B组进行连续性血液净化。比较两组患者各项指标的检测结果。结果:B组患者血清肌酐、尿素氮、血清钠、血清氯等检测值均低于A组;B组患者白细胞介素-6、肿瘤坏死因子检测值均低于A组,P<0.05。结论:重症胰腺炎患者应用血液净化治疗对于控制全身炎性反应综合征效果良好,但相对于间歇性血液净化来说,连续性血液净化技术效果更佳,可有效改善全身炎性反应综合征,值得推广。 Objective: To analyze the effects of blood purification therapy for patients with severe acute pancreatitis( SAP) in the control of systemic inflammatory response syndrome. Methods: 90 cases of SAP patients were randomly selected in 2013 April —2014 year in April in our hospital as the research object,and on the basis of the digital table method which were randomly divided into group A and group B,45 cases in each group; group A patients undergoing intermittent hemodialysis,B groups were treated with continuous blood purification. And then,the various indexes detected in both groups were compared. Results: The serum creatinine,blood urea nitrogen,serum sodium,serum chlorine were lower in group B than those in group A. Interleukin- 6,tumor necrosis factor were lower in group B than those in group A after treatment( P〈 0. 05). Conclusion: The effects of blood purification therapy on patients with severe acute pancreatitis to control systemic inflammatory response syndrome is good,and the continuous blood purification is better than intermittent hemodialysis. It can effectively improve the systemic inflammatory response syndrome and worthy of promotion.
作者 李强
出处 《青海医药杂志》 2015年第8期1-3,共3页 Qinghai Medical Journal
关键词 重症胰腺炎患者 血液净化治疗 全身炎性反应综合征 效果 Severe acute pancreatitis Blood purification treatment Systemic inflammatory response syndrome
  • 相关文献

参考文献6

二级参考文献51

  • 1张圣道,雷若庆.重症急性胰腺炎诊治指南[J].中国消化内镜,2007(10):34-36. 被引量:57
  • 2钱祝银,苗毅.重症急性胰腺炎治疗模式的转变与胰性脑病[J].中华外科杂志,2007,45(11):740-741. 被引量:9
  • 3王忠朝.重症急性胰腺炎病因、发病机理及治疗的临床研究进展[J].西藏医药,2007,28(3):19-22. 被引量:2
  • 4Mueller SC, MajchevPeszynska J, Hickstein H, et al. Pharmacokinetics of piperacillin tazobaetam in anuric intensive care patients during continuous venovenous hemodialysis[J]. Antimicrob Agents Chemother, 2002,46(5) : 1557-1560.
  • 5Valtonen M,Tiula E, Takkunem O,et al. Elimination of piperacillin/tazobaetam combination during continuous venovenous haemofiltration and haemodialfiltration in patients with acute renal failure[J]. J Antimierob Chemother,2001,48(6) : 881-885.
  • 6van der Werf T S,Mulder PO,Zijlstra JG,et al. Pharmacokinetics of piperacillin and tazobactam in critically ill patients with renal failure, treated with continuous veno-venous hemofiltration (CVVH) [J]. Intensive Care Med, 1997,23 (8) : 873- 877.
  • 7Cappellier G, Cornette C, Boillot A, et al. Removal of piperacillin in critically ill patients undergoing continuous venovenous hemofiltration[J]. Crit Care Med, 1998,26(1) : 88-91.
  • 8Trotman RL,Williamson JC,Shoemaker DM,et al. Antibiotic dosing in critically ill adult patients receiving continuous renal replacement therapy[J]. Clin Infect Dis, 2005,41 (8) : 1159- 1166.
  • 9Kroh UF, Lennartz H, Edwards D,et al. Pharmacokinetics of ceftriaxone in patients undergoing continuous veno-venous hemofiltration[J]. J Clin Pharmacol,1996,36(12) :1114-1119.
  • 10Matzke GR, Frye RF, Joy MS, et al. Determinants of ceftriaxone clearance by continuous venovenous hemofiltration and hemodialysis[J]. Pharmaeotherapy, 2000,20(6) : 635-643.

共引文献21

同被引文献20

引证文献3

二级引证文献36

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部